HTB: no. 11 – plus HIV and COVID-19 (30 November 2021)
PDF files use a single column layout that makes it easy to read on tablets and other hand held devices.
HTB 11 and HIV and COVID-19 – (30 November 2021)
This issue continues reports from the 18th EACS conference in London. Plus England approves injectable ART. Disappointing news that development of the investigational NNRTI MK-8507 has being stopped, with caution now on islatravir. An oral history programme for young people living with HIV. And the ever-comprehensive IAS 5-year review on HIV cure research is published for World AIDS Day.
Plus news on COVID-19 and vaccines.
Previous issues: 2021
HTB 10 and HIV and COVID-19 – (31 October 2021)
This issue leads with first reports from the 18th EACS hybrid conference, hosted in London. Other HIV news includes injectable ART approved in Scotland, results of the ANCHOR study for anal cancer screening, BHIVA guidelines for HIV-2 and explaining HIV remission/cure.
Plus news on COVID-19 and vaccines.
HTB 9 and HIV and COVID-19 – (17 September 2021)
This issue continues reports from the IAS 2021 conference and the 11th International Paediatric Workshop. It also includes the 2021 pipeline reviews of the next generation of HIV drugs. Plus Richard Jefferys review of the Imbokodo HIV vaccine study.
And an i-Base project with Modern ART for South Africa to produce resources on COVID-19 vaccines.
COVID-19 covers third vaccine doses in HIV positive people plus diverse news on many other aspect of vaccine research.
HTB 8 and HIV and COVID-19 – (1 August 2021)
This issue contains first reports from the IAS 2021 conference and the 11th International Paediatric Workshop. These focus on the latest HIV drugs and pipeline compounds.
The reports on COVID-19 include discussions on need for a third vaccine in come people and other vaccine developments. Treatment news includes inhaled budesonide, ivermection and azithromycin – plus other news…
HTB 7 and HIV and COVID-19 – (1 July 2021)
This issue contains HTB reports on vertical transmission in the UK, submission of lenacapavir to the FDA and updated US guidelines.
The reports on COVID-19 include using a third vaccine dose and toficitinib and REGN bNAbs as treatment; plus resources on Long COVID and more…
HTB 6 and HIV and COVID-19 – (1 June 2021)
This issue contains continued reports from both the excellent BHIVA/BASHH conference and CROI.
Plus 15 reports on COVID-19 – because the pace or research still makes this coverage important. This includes the new issue of how well vaccines work in people with reduced immune systems – for which there is little direct data.
HTB 5 and HIV and COVID-19 – (3 May 2021)
This issue includes an article to remember UK activist Paul Decle and first reports from the 5th BHIVA/BASHH conference including two important studies reporting HIV is an independent risk for worse COVID-19 outcomes. Other HIV news includes UK cutting funding to UNAIDS and the release of new NICE pain management guidelines.
The issue includes another 12 reports covering different aspects of COVID-19, including many that cover issues of vaccine efficacy and safety.
HTB 4 and HIV and COVID-19 – (1 April 2021)
This issue includes second reports from the CROI 2021 virtual conference, including lenacapavir, pregnancy and weight outcomes from dolutegravir and TAF and important results from research into treatments for COVID-19. Plus news from BHIVA on COVID-19 including vaccines.
HTB 3 and HIV and COVID-19 – (12 March 2021)
This issue includes early reports from the CROI 2021 virtual conference, including new HIV drugs in development, the NADIA study, a revised understanding of the HIV life cycle and important results from research into treatments for COVID-19.
HTB 2 and HIV and COVID-19 – (24 February 2021)
This issue remembers two activists, Elias Phiri and Dr Joseph Sonnabend, and links to a virtual memorial for Timothy Ray Brown.
We include three reports from the R4P HIV prevention conference including the long-awaited results from the AMP studies.
i-Base news includes murals from Soweto on TLD.
COVID-19 news is also significant this issue, with nine reports linked to vaccines and four to new treatment. Also that COVID-19 cases in African might be vastly underestimated and that the B.1.1.7 variant in the UK more pathogenic as well as being easier to transmit.
HTB 1 and HIV and COVID-19 – (22 January 2021)
This first issue of 2021 includes important news about new HIV drug approvals, an important report about drug resistance to first-line ART in South Africa, plus latest UK figures on LGV, and on sexual health during COVID-19.
Plus numerously reports on rapidly changing news relating to vaccine and treatment for COVID-19. This include promising news about new treatments, including colcochine, IV methylprednisolone, dual monoclonal antibody combinations and IL-6 antagonists (tocilizumab).
Previous issues: 2020
HTB 13/14 and HIV and COVID-19 no 10 – (9 December 2020)
HTB news in this issue includes access to paediatric dolutegravir, and drug resistance in Malawi. Coverage of COVID-19 includes important updates on vaccine research and access for HIV positive people in the UK plus disappointing results from the WHO SOLIDARITY and Barcelona PEP studies – questioning the use of HCQ or LOP/r as treatment in early infection.
HTB 12 and HIV and COVID-19 no 9 – (11 November 2020)
This issue includes reports from three medical conferences plus the new statistics from Public Health England showing that HIV infections continued to fall during 2019. Also, that cabotegravir LA/rilpivirine LA injections will be approved in the EU. Coverage of COVID-19 includes the already widely known news about the early efficacy results of the Pfizer/BioNTech vaccine and less optimistic results from using monoclonal antibodies or convalescent plasma as treatment.
HTB and HIV and COVID-19 no 8 – (14 October 2020)
Another double issue (September and October) combines HTB reports from HIV Glasgow 2020 with the supplement on COVID-19. HIV news includes pipeline drugs, weight gain, PEP guidelines and cure research. COVID-19 news includes new studies on HIV coinfection, tocilizumab, reinfections plus other news.
HTB and HIV and COVID-19 no 7 – (28 August 2020)
Double issue combines HTB reports from AIDS 2020 with the supplement on COVID-19. HIV news includes weight gain and integrase inhibitors, FDA and EMA announcements, video links and concern over proposal to end Public Health England (PHE). COVID-19 news includes two UK studies on HIV coinfection, treatment updates on tocilizumab and famotidine, plus vaccine news.
HTB and HIV and COVID-19 no 6 – (22 July 2020)
This extended issue – 40 pages – combines HTB which has first reports from the AIDS 2020 conference with the supplement on COVID-19. Important COVID-19 news includes more studies on HIV coinfection and COVID-19.
HIV and COVID-19 no 5 – (26 June 2020)
HIV and COVID-19 coinfections including data from South Africa, dexamethasone effective in advanced COVID-19, hydroxycholoquine not effective in UK RECOVERY study, plus updates on remdesivir and other treatments…
HIV and COVID-19 no 4– (1 June 2020)
HIV and COVID-19 coinfections, UK access to remdesivir, convalescent plasma, interferon, famotidine, tocilizumab, concern with hydroxychloroquine, UK research plus more…
HIV and COVID-19 no 3 – (14 May 2020)
Latest issue includes news on latest treatments, including US approval of remdesivir, plus tentative results with other drugs that reduce immune inflammation – perhaps just as essential to use as antivirals.
HIV and COVID-19: no 2 – (17 April 2020)
The second supplement of HTB with more than 30 COVID-19 reports.
HIV and COVID-2019: no 1 – (27 March 2020)
This 20-page HTB supplement compiles links to articles and resources about COVID-19 including information for managing the care of HIV positive people. It includes short reviews of key studies and early guidelines.
Other news and resources on COVID-19 are at: